Covid-19 aAPC Vaccine / SZGIMI - LARVOL DELTA

Safety and Immunity of Covid-19 aAPC Vaccine (clinicaltrials.gov) - P1 | N=100 | Terminated | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2030 ➔ Jul 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2029 ➔ Jul 2026

Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

Safety and Immunity of Covid-19 aAPC Vaccine (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2024 ➔ Dec 2030 | Trial primary completion date: Jul 2023 ➔ Dec 2029

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

The COVID-19 puzzle: a global nightmare. (PubMed, Environ Dev Sustain) - "mRNA-1273, ChAdOx1, Ad5-nCoV, INO-4800, LV-SMENP-DC and pathogen-specific aAPC are the most advanced and potential drug candidates against COVID-19. Recent studies have revealed any attractive vaccine candidates as promising therapeutic agents based on different strategies of vaccines. Here, the rationale of this review was also to provide an overview of the pathogenesis of the virus and summarize the updated potential vaccine candidates against SARS-CoV-2."

Clinical • Journal • Review • Infectious Disease • Novel Coronavirus Disease • Otorhinolaryngology • Pain • Pneumonia • Respiratory Diseases